PanTera leverages a patented photo-nuclear “gamma” production process to transform Radium-226 into Radium-225, which decays into clinical-grade actinium-225 (225Ac). The company aims to enable annual production of more than 100 Curies of clinical-grade 225Ac by 2029, supporting treatment of over 100,000 patients per year. PanTera plans to bring its commercial production facility online in Belgium, funded in part by the recent raise. In parallel, it is supplying early quantities of 225Ac via an alternative production method and, working with TerraPower Isotopes, expects to provide 1.5–2 Ci annually from early 2025. The company has signed supply agreements with several pharmaceutical companies, including Bayer, and expects to have secured agreements for more than 80% of its capacity before production starts. PanTera is led by CEO Sven Van den Berghe.

Total raised

$148M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Sep 2024